UNITED
STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549



FORM 10-K/A

(Amendment No. 1)

(Mark One)



x ANNUAL REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended: December 31, 2015



 ̈ TRANSITION REPORT PURSUANT TO SECTION
13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ____________ to _____________



Commission File No. 001-34566



CHINA BIOLOGIC
PRODUCTS, INC.(Exact name of registrant as specified in its charter)



|Delaware                                                       | 75-2308816                          
|-------------------------------------------------------------- | ------------------------------------
|(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.)



18th Floor, Jialong International Building,
19 Chaoyang Park RoadChaoyang District, Beijing 100125People’s Republic of China(Address of principal executive offices)



(+86) 10-6598-3111(Registrant’s telephone number, including area code)



Securities registered pursuant to Section 12(b) of the Act:





|Title of each class                                                               |  | Name of each exchange on which registered                      
|--------------------------------------------------------------------------------- |  | ---------------------------------------------------------------
|Common Stock, par value $0.0001 per share
        Preferred Share Purchase Rights |  | NASDAQ Global Select Market
        NASDAQ Global Select Market







Securities registered pursuant to Section
12(g) of the Exchange Act: None



Indicate by check mark if the registrant
is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes x        
No  ̈



Indicate by check mark if the registrant
is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes  ̈        
No x



Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes x No  ̈



Indicate by check mark whether the registrant
has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted
and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such
shorter period that the registrant was required to submit and post such files) Yes x        
No  ̈



Indicate by check mark if disclosure of
delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405 of this chapter) is not contained herein, and will not
be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference
in Part III of this Form 10-K or any amendment to this Form 10-K.  ̈



Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions
of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2
of the Exchange Act.



|Large Accelerated Filer x                                            | Accelerated Filer  ̈        
|-------------------------------------------------------------------- | ---------------------------
|                                                                     |                            
|Non-Accelerated Filer  ̈(Do not check if a smaller reporting company) | Smaller reporting company  ̈



|Indicate by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes  ̈         No x                                                                                                                                                                                                                                                          
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|                                                                                                                                                                                                                                                                                                                                                                                
|The aggregate market value of common stock
        held by non-affiliates of the registrant, based upon the closing sale price on June 30, 2015 as reported on the NASDAQ Global Select
        Market, was approximately $1,983 million.
        
        There were a total of 26,590,974 shares of the registrant’s
        common stock outstanding as of February 25, 2016.
|                                                                                                                                                                                                                                                                                                                                                                                
|DOCUMENTS INCORPORATED BY REFERENCE                                                                                                                                                                                                                                                                                                                                             
|                                                                                                                                                                                                                                                                                                                                                                                
|Portions of the registrant’s Proxy Statement for its 2016 Annual Meeting of Stockholders to be filed with the Commission within 120 days after the close of the registrant’s fiscal year are incorporated by reference into Part III of this annual report on Form 10-K.                                                                                                        













Table
of Contents





|EXPLANATORY NOTE                                                                                                       | 3
|---------------------------------------------------------------------------------------------------------------------- | -
|ITEM 5.  MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES. | 4
|ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES.                                                                      | 5
|SIGNATURES                                                                                                             | 6
|EXHIBIT INDEX                                                                                                          | 7

2







Explanatory
Note



We are filing this Amendment No. 1 (this
“Amendment”) to our annual report on Form 10-K for the fiscal year ended December 31, 2015 (the “Original Form
10-K”), which was originally filed with the Securities and Exchange Commission on February 25, 2016, for the sole purpose
of revising information set forth in the section captioned “Securities Authorized for Issuance under Equity Compensation
Plans” under Item 5 provided pursuant to Item 201(d) of Regulation S-K. This Amendment does not affect the information in
the other sections under Item 5 of the Original Form 10-K.



In addition, we are also filing new certifications
by our principal executive officer and principal financial officer as exhibits to this Amendment pursuant to Rule 13a-14(a) of
the Securities Exchange Act of 1934, as amended. Therefore, this Amendment also updates the list of exhibits under Item 15 of the
Original Form 10-K by incorporating such new certifications filed as Exhibits 31.1 and 31.2 hereto. We are not including certifications
pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. 1350) as no financial statements are being
filed with this Amendment.



No other changes have been made to the
Original Form 10-K. This Amendment does not reflect events that have occurred after the filing of the Original Form 10-K, or modify
or update the disclosures presented therein, except to reflect the amendment described above.



3









PART II



ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED
STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.



Securities Authorized for Issuance under
Equity Compensation Plans



The following table includes the information
as of December 31, 2015 for each category of our equity compensation plan:



|Plan category                                              |  | Number of securities to be issued upon exercise of outstanding options, warrants and rights (a) (1) |         |  | Weighted-average exercise price of outstanding options, warrants and rights (b) |   |       | Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) (c) | 
|---------------------------------------------------------- |  | --------------------------------------------------------------------------------------------------- | ------- |  | ------------------------------------------------------------------------------- | - | ----- | ----------------------------------------------------------------------------------------------------------------------------------------------- | 
|Equity compensation plans approved by security holders(2)  |  |                                                                                                     | 651,897 |  |                                                                                 | $ | 10.44 |                                                                                                                                                 | 
|Equity compensation plans not approved by security holders |  |                                                                                                     | -       |  |                                                                                 |   | -     |                                                                                                                                                 | 
|Total                                                      |  |                                                                                                     | 651,897 |  |                                                                                 | $ | 10.44 |                                                                                                                                                 | 



| | (1) | Excludes shares of restricted stock granted pursuant to our 2008 Equity Incentive Plan, or the
2008 Plan. The 669,100 shares of unvested restricted stock at December 31, 2015 are issuable without the payment of any cash consideration
by the grantee.
| | --- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | (2) | Our board of directors adopted the 2008 Plan on May 9, 2008 and shortly thereafter sought and obtained
approval by written consent from the holders of a majority of our then outstanding shares, which we believed was effective approval
under the Delaware General Corporation Law. However, in response to an SEC comment in 2010, the disclosure in the foregoing table
was revised for presently unknown reasons to reflect that the 2008 Plan was not approved by our stockholders. We have recently
reviewed our records relating to the 2008 approval of the 2008 Plan. While the 2008 Plan was approved by stockholders holding a
majority of our stock acting by written consent, and therefore we believe that the 2008 Plan was approved, in connection with the
recent review of our records, we recognized that there may be some technical defects in the manner in which the approval was obtained
in 2008. We are in the process of collecting additional information and will continue our analysis of whether such stockholder
approval complied with all the technical requirements of Delaware law and will take appropriate steps in light of that assessment.
| | --- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



The 2008 Plan provides for grants of stock
options, stock appreciation rights, performance units, restricted stock, restricted stock units and performance shares. A total
of five million shares of our common stock may be issued pursuant to the 2008 Plan. The exercise price per share for the shares
to be issued pursuant to an exercise of a stock option will be no less than the fair market value per share on the grant date,
except that, in the case of an incentive stock option granted to a person who holds more than 10.0% of the total combined voting
power of all classes of our stock or any of our subsidiaries, the exercise price will be no less than 110.0% of the fair market
value per share on the grant date. As of December 31, 2015, 669,100 shares of restricted stock and options to purchase 651,897
share of our common stock were outstanding. No awards may be granted under the 2008 Plan after May 9, 2018, except that any award
granted before then may extend beyond that date.



4









PART IV



ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES.



Exhibit List



The list of exhibits in the Exhibit Index to this Report is
incorporated herein by reference.



5









SIGNATURES



In accordance with section 13 or 15(d) of the Securities Exchange
Act of 1934, the registrant caused this Amendment No.1 to the Annual Report on Form 10-K to be signed on its behalf by the undersigned,
thereto duly authorized individual.



Date: November 2, 2016.





|CHINA BIOLOGIC PRODUCTS, INC.               | 
|------------------------------------------- | 
|                                            | 
|By:  /s/
    David (Xiaoying) Gao           | 
|David (Xiaoying) GaoChief Executive Officer | 
|                                            | 



6









POWER OF ATTORNEY



KNOW ALL PERSONS BY THESE PRESENTS, that
each person whose signature appears below constitutes and appoints David (Xiaoying) Gao and Ming Yang, jointly and severally, as
his true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him and in his name,
place and stead, in any and all capacities, to sign this Amendment No. 1 to Form 10-K, and to file the same, with all exhibits
thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact
and agents full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about
the premises hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or their substitute or substitutes,
may lawfully do or cause to be done by virtue hereof.



Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the
registrant in the capacities and on the dates indicated.





|Signature                    |  | Title                                         | Date            
|---------------------------- |  | --------------------------------------------- | ----------------
|                             |  |                                               |                 
|/s/ David (Xiaoying) Gao     |  | Chairman and Chief Executive Officer          | November 1, 2016
|David (Xiaoying) Gao         |  | (Principal Executive Officer)                 |                 
|                             |  |                                               |                 
|/s/ Ming Yang                |  | Chief Financial Officer                       | November 1, 2016
|Ming Yang                    |  | (Principal Financial and Accounting Officer ) |                 
|                             |  |                                               |                 
|/s/ Sean Shao                |  | Director                                      | November 1, 2016
|Sean Shao                    |  |                                               |                 
|                             |  |                                               |                 
|/s/ Joseph Chow              |  | Director                                      | November 1, 2016
|Joseph Chow                  |  |                                               |                 
|                             |  |                                               |                 
|/s/ Yungang Lu               |  | Director                                      | November 1, 2016
|Yungang Lu                   |  |                                               |                 
|                             |  |                                               |                 
|/s/ David Hui Li             |  | Director                                      | November 1, 2016
|David Hui Li                 |  |                                               |                 
|                             |  |                                               |                 
|/s/ Wenfang Liu              |  | Director                                      | November 1, 2016
|Wenfang Liu                  |  |                                               |                 
|                             |  |                                               |                 
|/s/ Albert (Wai Keung) Yeung |  | Director                                      | November 1, 2016
|Albert (Wai Keung) Yeung     |  |                                               |                 
|                             |  |                                               |                 
|                             |  | Director                                      |                 
|Zhijun Tong                  |  |                                               |                 



7









EXHIBIT INDEX



|Exhibit No. |  | Description                                                                                                                                                                                                                                                                
|----------- |  | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|2.1         |  | Share Exchange Agreement between the registrant, Logic Express Limited and the selling stockholders signatory thereto, dated July 18, 2006 (incorporated by reference to Exhibit 2 of the registration statement on Form SB-2 filed by the registrant on September 5, 2007)
|3.1         |  | Second Amended and Restated Certificate of Incorporation of China Biologic Products, Inc. (incorporated by reference to Exhibit 3.1 of the quarterly report on Form 10-Q filed by the registrant on August 5, 2014)                                                        
|3.2         |  | Third Amended and Restated Bylaws of China Biologic Products, Inc. (incorporated by reference to Exhibit 3.2 of the quarterly report on Form 10-Q filed by the registrant on August 5, 2014)                                                                               
|4.1         |  | Form of Registration Rights Agreement, dated June 5, 2009 (incorporated by reference to Exhibit 4.1 of the current report on Form 8-K filed by the registrant on June 5, 2009)                                                                                             
|4.2         |  | Form of 3.8% Convertible Senior Secured Note due 2011 (incorporated by reference to Exhibit 4.2 of the current report on Form 8-K filed by the registrant on June 5, 2009)                                                                                                 
|4.3         |  | Form of Warrant (incorporated by reference to Exhibit 4.3 of the current report on Form 8-K filed by the registrant on June 5, 2009)                                                                                                                                       
|4.4         |  | Certificate of Designation of Rights, Preferences and Privileges of Series A Participating Preferred Stock of China Biologic Products, Inc. (incorporated by reference to Exhibit 3.1 of the registration form on Form 8-A12B filed by the registrant on November 21, 2012)
|4.5         |  | Preferred Shares Rights Agreement, between the registrant and Securities Transfer Corporation, dated as of January 8, 2015 (incorporate by reference to Exhibit 4.1 of the current report on Form 8-K filed by the registrant on January 9, 2015)                          
|10.1        |  | China Biologic Products, Inc. 2008 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 of the current report on Form 8-K filed by the registrant on May 13, 2008)                                                                                             
|10.2        |  | Form of Stock Option Award Agreement of China Biologic Products, Inc. (incorporated by reference to  Exhibit 10.5 of the current report on Form 8-K filed by the registrant on May 13, 2008)                                                                               
|10.3        |  | Form of Restricted Stock Award Agreement of China Biologic Products, Inc. (incorporated by reference to Exhibit 3.3 of the current report on Form 8-K filed by the registrant on August 6, 2011)                                                                           
|10.4        |  | Group Secondment Agreement, dated October 28, 2002, between Shandong Taibang and the Shandong Institute (English Translation) (incorporated by reference to Exhibit 10.1 of the registration statement on Form SB-2/A filed by the registrant on December 3, 2007)         





8







|10.5  |  | Amended and Restated Joint Venture Agreement, between Logic Express Limited and the Shandong Institute, dated as of March 12, 2006 (English Translation) (incorporated by reference to Exhibit 10.2 of the registration statement on Form SB-2 filed by the registrant on September 5, 2007)                                                                                                  
|----- |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|10.6  |  | Letter of Intent for Equity Transfer, between Logic Express Limited and the Shandong Institute, dated as of June 10, 2006 (English Translation) (incorporated by reference to Exhibit 10.3 of the registration statement on Form SB-2 filed by the registrant on September 5, 2007)                                                                                                           
|10.7  |  | Joint Venture and Cooperation Agreement between Mr. Fan Qingchun, Shandong Taibang and Shaanxi Power Construction Corporation, dated September 12, 2008 (incorporated by reference to Exhibit 10.2 of the current report on Form 8-K filed by the registrant on October 16, 2008)                                                                                                             
|10.8  |  | Agreement on Equity Transfer, Acquisition, Joint Venture and Cooperation, among Shandong Taibang, Shaanxi Power Construction Corporation and Mr. Fan Qingchun, dated September 12, 2008 (incorporated by reference to Exhibit 10.3 of the current report on Form 8-K filed by the registrant on October 16, 2008)                                                                             
|10.9  |  | (Shareholder) Agreement among Shandong Taibang, Logic Express Limited and Biological Institute dated September 12, 2008 (incorporated by reference to Exhibit 10.4 of the current report on Form 8-K, filed by the registrant on October 16, 2008)                                                                                                                                            
|10.10 |  | Equity Transfer Agreement, dated September 26, 2008, among Logic Express Limited, Chongqing Dalin Biologic Technologies Co., Ltd. and certain shareholders of Chongqing Dalin Biologic Technologies Co., Ltd. (incorporated by reference to Exhibit 10.1 of the current report on Form 8-K filed by the registrant on October 2, 2008)                                                        
|10.11 |  | Equity Transfer Agreement, between Shandong Taibang and Mr. Fan Qingchun, dated October 10, 2008 (incorporated by reference to Exhibit 10.1 of the current report on Form 8-K filed by the registrant on October 16, 2008)                                                                                                                                                                    
|10.12 |  | Supplemental Agreement, dated November 3, 2008, among Logic Express Limited, Fan Shaowen, as representative of the shareholders of Chongqing Dalin Biologic Technologies Co., Ltd. and Chongqing Dalin Biologic Technologies Co., Ltd. (English Translation) (incorporated by reference to Exhibit 10.2 of the current report on Form 8-K filed by the registrant on November 7, 2008)        
|10.13 |  | Second Supplemental Agreement, dated November 14, 2008, among Logic Express Limited, Fan Shaowen as representative of the shareholders of Chongqing Dalin Biologic Technologies Co., Ltd. and Chongqing Dalin Biologic Technologies Co., Ltd. (English Translation) (incorporated by reference to exhibit 10.3 of the current report on Form 8-K filed by the registrant on November 20, 2008)
|10.14 |  | Amended Equity Transfer Agreement, dated December 12, 2008, among Logic Express Limited, Chongqing Dalin Biologic Technologies Co., Ltd., and certain shareholders of Chongqing Dalin Biologic Technologies Co., Ltd. (English Translation) (incorporated by reference to exhibit 10.4 of the current report on Form 8-K filed by the registrant on December 18, 2008)                        





9







|10.15 |  | Equity Transfer and Entrustment Agreement, dated April 6, 2009, among Logic Express, Shandong Taibang and the Shandong Institute (English Translation) (incorporated by reference to Exhibit 10.6 of the current report on Form 8-K filed by the registrant on April 13, 2009)                                                                     
|----- |  | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|10.16 |  | Asset Purchase Agreement, between Xia Jin An Tai Plasma Collection Co., Ltd. and Xia Jin County Plasma Collection Station, dated as of October 20, 2006 (English Translation) (incorporated by reference to Exhibit 10.15 of the registration statement on Form SB-2/A filed by the registrant on December 3, 2007)                                
|10.17 |  | Asset Purchase Agreement, between Liao Cheng An Tai Plasma Collection Co., Ltd. and Yang Gu County Plasma Collection Station, dated as of November 3, 2006 (English Translation) (incorporated by reference to Exhibit 10.16 of the registration statement on Form SB-2/A filed by the registrant on December 3, 2007)                             
|10.18 |  | Asset Purchase Agreement, between Qi He An Tai Plasma Collection Co., Ltd. and Qi He County Plasma Collection Station, dated as of November 9, 2006 (English Translation) (incorporated by reference to Exhibit 10.14 of the registration statement on Form SB-2/A filed by the registrant on December 3, 2007)                                    
|10.19 |  | Asset Purchase Agreement, between He Ze An Tai Plasma Collection Co., Ltd and Yun Cheng County Plasma Collection Station, dated as of December 15, 2006 (English Translation) (incorporated by reference to Exhibit 10.22 of the registration statement on Form SB-2/A filed by the registrant on December 3, 2007)                                
|10.20 |  | Asset Purchase Agreement, between Zhang Qiu An Tai Plasma Collection Co., Ltd. and Zhang Qiu Plasma Collection Station, dated as of December 31, 2006 (English Translation) (incorporated by reference to Exhibit 10.12 of the registration statement on Form SB-2/A filed by the registrant on December 3, 2007)                                  
|10.21 |  | Asset Purchase Agreement, between Guang Xi Huan Jiang Missile Plasma Collection Co., Ltd. and Huan Jiang Maonan Autonomous County Plasma Collection Station, dated as of April 24, 2007 (English Translation) (incorporated by reference to Exhibit 10.13 of the registration statement on Form SB-2/A filed by the registrant on December 3, 2007)
|10.22 |  | Asset Purchase Agreement, between Fang Cheng Plasma Collection Co., Ltd. and Fang Cheng Plasma Company, dated as of April 30, 2007 (English Translation) (incorporated by reference to Exhibit 10.21 of the registration statement on Form SB-2/A filed by the registrant on December 3, 2007)                                                     
|10.23 |  | Asset Purchase Agreement, between Guang Xi Huan Jiang Missile Plasma Collection Co., Ltd. and Huan Jiang Maonan Autonomous County Plasma Collection Station, dated as of August 5, 2007 (English Translation) (incorporated by reference to Exhibit 10.13 of the registration statement on Form SB-2/A filed by the registrant on December 3, 2007)
|10.24 |  | Trademark Licensing Agreement, dated as of February 27, 2007 (English Translation) (incorporated by reference to Exhibit 10.17 of the registration statement on Form SB-2/A filed by the registrant on December 3, 2007)                                                                                                                           
|10.25 |  | Loan Agreement, dated as of November 30, 2006, among Shandong Taibang and the Shandong Institute and Logic Express (English Translation) (incorporated by reference to Exhibit 10.18 of the registration statement on Form SB-2/A filed by the registrant on December 3, 2007)                                                                     





10







|10.26 |  | Supplementary Agreement, dated as of September 1, 2007, among Shandong Taibang, the Shandong Institute and Logic Express Limited (English Translation) (incorporated by reference to Exhibit 10.19 of the registration statement on Form SB-2/A filed by the registrant on December 3, 2007)                
|----- |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|10.27 |  | Employment Agreement, between David (Xiaoying) Gao and the registrant, dated May 11, 2014 (incorporated by reference to Exhibit 10.1 of the current report on Form 8-K filed by the registrant on May 15, 2014)                                                                                             
|10.28 |  | Form of Director’s Employment Agreement (incorporated by reference to Exhibit 10.8 of the registration statement on Form SB-2 filed by the registrant on September 5, 2007)                                                                                                                                 
|10.29 |  | Form of Independent Director Agreement (incorporated by reference to Exhibit 10.1 of the current report on Form 8-K filed by the registrant on July 30, 2008)                                                                                                                                               
|10.30 |  | Form of Indemnity Agreement (incorporated by reference to Exhibit 10.2 of the current report on Form 8-K filed by the registrant on July 30, 2008)                                                                                                                                                          
|10.31 |  | Form of Guarantee and Pledge Agreement, dated June 10, 2009 (incorporated by reference to Exhibit 10.2 of the current report on Form 8-K filed by the registrant on June 5, 2009).                                                                                                                          
|10.32 |  | Form of Indemnification Agreement, dated June 10, 2009 (incorporated by reference to Exhibit 10.3 of the current report on Form 8-K filed by the registrant on June 5, 2009).                                                                                                                               
|10.33 |  | Cooperation Agreement, among Guizhou Taibang, Xinjiang Deyuan and its controlling shareholder, dated August 28, 2015 (Summary English Translation) (incorporated by reference to Exhibit 10.1 of the current report on Form 8-K filed by the registrant on September 2, 2015)                               
|10.34 |  | Supplemental Agreement, between Guizhou Taibang and Xinjiang Deyuan, dated April 16, 2015 (Summary English Translation) (incorporated by reference to Exhibit 10.2 of the current report on Form 8-K filed by the registrant on April 16, 2015)                                                             
|10.35 |  | Cooperation Agreement, between Guizhou Taibang and Xinjiang Deyuan, dated September 30, 2014 (Summary English Translation) (incorporated by reference to Exhibit 10.1 of the current report on Form 8-K filed by the registrant on April 16, 2015)                                                          
|10.36 |  | Registered Equity Purchase Agreement, between Guiyang Dalin Biotechnology Co., Ltd. and Guizhou Eakan Pharmaceutical Co., Ltd., dated August 21, 2014 (Summary English Translation) (incorporated by reference to Exhibit 10.1 of the current report on Form 8-K filed by the registrant on August 25, 2014)
|10.37 |  | Equity Exchange Agreement, between Guiyang Dalin Biotechnology Co., Ltd. and Guizhou Eakan Pharmaceutical Co., Ltd., dated August 21, 2014 (Summary English Translation) (incorporated by reference to Exhibit 10.2 of the current report on Form 8-K filed by the registrant on August 25, 2014)           





11







|10.38   |  | Unregistered Equity Purchase Agreement, between Guiyang Dalin Biotechnology Co., Ltd. and Guizhou Eakan Pharmaceutical Co., Ltd., dated August 21, 2014 (Summary English Translation) (incorporated by reference to Exhibit 10.3 of the current report on Form 8-K filed by the registrant on August 25, 2014)
|------- |  | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|14      |  | Code of Ethics (incorporated by reference to Exhibit 14 of the annual report on Form 10-KSB filed by the registrant on March 28, 2008)                                                                                                                                                                        
|21*     |  | Subsidiaries of the registrant                                                                                                                                                                                                                                                                                
|23.1*   |  | Consent of KPMG, an independent registered public accounting firm                                                                                                                                                                                                                                             
|24.1    |  | Power of Attorney (included on the Signature
Page of this Amendment No. 1 to Annual Report on Form 10–K)                                                                                                                                                                                                      
|31.1*** |  | Certifications of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002                                                                                                                                                                                                           
|31.2*** |  | Certifications of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002                                                                                                                                                                                                           
|32.1**  |  | Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002                                                                                                                                                                                                            
|32.2**  |  | Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002                                                                                                                                                                                                            
|101*    |  | Interactive data files pursuant to Rule 405 of Regulation S-T                                                                                                                                                                                                                                                 



*Previously filed with our Annual Report
on Form 10-K for the year ended December 31, 2015, as filed on February 25, 2016.

**Previously furnished with our Annual
Report on Form 10-K for the year ended December 31, 2015, as filed on February 25, 2016.

***Filed herewith.

12